Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 19, 2004

View Archived Issues

Ranbaxy scientists describe new iminosugar-based anticancer agents

Novel polo-like kinase inhibitors developed at GSK

New GLP-1 analogues and their use covered by SCRAS patent

Theravance researchers claim dual beta2-AR agonists/muscarinic antagonists

Novel 5-HT6 receptor ligands in early development at Wyeth

New p38 MAP kinase inhibitors identified by GSK researchers

New peptide with vasodilatory activity isolated from frog skin secretion

Chiesi scientists prepare and test new gamma-secretase inhibitors for AD

R&D highlights from the 4th Annual Biotech In Europe Investor Forum: CareX

R&D highlights from the 4th Annual Biotech In Europe Investor Forum: Chroma Therapeutics

R&D highlights from the 4th Annual Biotech In Europe Investor Forum: DeveloGen

Positive in vivo report comparing MDI-P to tobramycin

Positive phase III results for Neupro in advanced Parkinson's

UCB Pharma in Parkinson's collaboration with Brigham and Women's Hospital

UCB Pharma to discontinue Olux, Luxiq copromotion

Remicade receives European approval for psoriatic arthritis

Approvable letter for Riquent

Niaspan approved in France

Luveris approved for concomitant use with Gonal-f

Potential clinical effects reported for the HIV-1 integrase inhibitor L-870810

CoFactor designated orphan drug in Europe for pancreatic cancer

Symadex enters second phase I study

Benefits of a good adherence to bisphosphonates in patients with osteoporosis

New data on the therapeutic effects of raloxifene in osteoporosis

Topiramate as a novel approach to alcoholism

Conclusion of dose-escalating phase I study for DB-289

RPI-78M successfully completes studies in MS animal model

Encouraging interim results from phase I study of ACP-HIP

Viventia Biotech seeks orphan drug status for Proxinium

InNexus to develop S(T15) SuperAntibody for coronary heart disease

Proposed merger of Aventis into sanofi-aventis

Activation of PARP and erectile dysfunction

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...